Abstract:The Kirsten rat sarcoma viral (KRAS) oncogene is the most frequently mutated isoform of RAS, associated with 85 % of RAS-driven cancers. KRAS functions as a signaling hub, participating in various cellular signaling pathways and regulating a wide range of important activities, including cell proliferation, differentiation, growth, metabolism, and migration. Despite being the most frequently altered oncogenic protein in solid tumors, over the past four decades, KRAS has historically been considered "undruggable" owing to a lack of pharmacologically targetable pockets within the mutant isoforms. However, improvements in drug design and development have culminated in the development of selective inhibitors for KRAS mutants. Recent developments have led to the successful targeting of the KRASG12C mutant through covalent inhibitors that exploit the unique cysteine residue introduced by the mutation at 12th position. These inhibitors bind covalently to C12, locking KRAS in its inactive GDP-bound state and preventing downstream signaling. Some of these inhibitors have shown encouraging results in KRASG12C mutant cancer patients but suffer from drug resistance, toxicity, and low therapeutic efficacy. Recently, there have been great advancements in the discovery of drugs that directly target the switch I (S-I), switch-II (S-II) and S-I/II interface sites of KRAS mutant proteins. These include KRASG12C inhibitors like AMG510 (Sotorasib) and MRTX849 (Adagrasib), which have got FDA approval for non-small cell lung cancer harboring the KRASG12C mutation. There is no approved drug for cancers harboring other KRAS mutations, although efforts have expanded to target other KRAS mutations and the Switch I/II interface, aiming to disrupt KRAS-driven oncogenic signaling. Structure-activity relationship (SAR) studies have been instrumental in optimizing the binding affinity, selectivity, and pharmacokinetic properties of these inhibitors, leading to the development of promising therapeutic agents like Sotorasib and Adagrasib. This review provides an overview of the KRAS pathway, KRAS binding sites, strategies for direct and indirect inhibition using small molecules, and SAR based on the co-crystal structures of inhibitors with KRAS mutants which is expected to offer new hope for patients with KRAS-driven cancers through the development of new KRAS-targeted drugs.

Inhibitors of the GTPase KRASG12C in Cancer: a Patent Review (2019-2021).

Inhibition of GTPase KRASG12D: a review of patent literature

Recent advances in the development of inhibitors targeting KRAS-G12C and its related pathways

Research Progress on Small Molecule Inhibitors Targeting KRAS G12C with Acrylamide Structure and the Strategies for Solving KRAS Inhibitor Resistance

KRAS mutation: from undruggable to druggable in cancer

Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges

From bench to bedside: current development and emerging trend of KRAS-targeted therapy

The path to the clinic: a comprehensive review on direct KRASG12C inhibitors

Annual Review of KRAS Inhibitors in 2022.

Targeting KRAS in Colorectal Cancer

Covalent inhibitor targets KRasG12C: A new paradigm for drugging the undruggable and challenges ahead

Small-Molecule Inhibitors Directly Targeting KRAS as Anticancer Therapeutics

Drugging KRAS: current perspectives and state-of-art review

Structural insights into small-molecule KRAS inhibitors for targeting KRAS mutant cancers

Multiple medicinal chemistry strategies of targeting KRAS: State-of-the art and future directions

Targeting KRAS in cancer

Repotrectinib Increases KRAS-G12C Inhibitor Effectiveness Via Simultaneous Inhibition of SRC, FAK, and JAK2

The next-generation KRAS inhibitors…What comes after sotorasib and adagrasib?

The KRAS-G12C inhibitor: activity and resistance

Targeting small GTPases: emerging grasps on previously untamable targets, pioneered by KRAS

Structural perspectives on recent breakthrough efforts toward direct drugging of RAS and acquired resistance